These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2144819

  • 21. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M, Serretta V, Pavone C, Romano C, Daricello G.
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
    de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):965-9. PubMed ID: 2149509
    [Abstract] [Full Text] [Related]

  • 24. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Dec 20; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 25. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM.
    J Urol; 1988 Dec 20; 140(6):1460-5. PubMed ID: 2973529
    [Abstract] [Full Text] [Related]

  • 26. LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
    Denis L.
    Horm Res; 1989 Dec 20; 32 Suppl 1():66-7; discussion 68. PubMed ID: 2533158
    [Abstract] [Full Text] [Related]

  • 27. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, de Jong FH, Klijn JG, Matroos AW, de Voogt HJ.
    J Urol; 1987 May 20; 137(5):912-8. PubMed ID: 2952810
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men.
    Knuth UA, Hano R, Nieschlag E.
    J Clin Endocrinol Metab; 1984 Nov 20; 59(5):963-9. PubMed ID: 6237116
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
    Ayub M, Levell MJ.
    Clin Endocrinol (Oxf); 1990 Mar 20; 32(3):329-39. PubMed ID: 2140542
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ.
    Urology; 1997 Sep 20; 50(3):330-6. PubMed ID: 9301693
    [Abstract] [Full Text] [Related]

  • 35. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O'Donoghue EP, Sikora K.
    Am J Clin Oncol; 1988 Sep 20; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [Abstract] [Full Text] [Related]

  • 36. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH.
    Prog Clin Biol Res; 1990 Sep 20; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
    Schulze H, Kaldenhoff H, Senge T.
    Urol Int; 1988 Sep 20; 43(4):193-7. PubMed ID: 2973169
    [Abstract] [Full Text] [Related]

  • 38. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ.
    Horm Res; 1989 Sep 20; 32 Suppl 1():69-76. PubMed ID: 2533159
    [Abstract] [Full Text] [Related]

  • 39. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
    Huhtaniemi I, Parvinen M, Venho P, Rannikko S.
    Int J Androl; 1991 Oct 20; 14(5):374-86. PubMed ID: 1839022
    [Abstract] [Full Text] [Related]

  • 40. Initiation of LHRH monotherapy for prostate cancer.
    Milsted RA.
    Prog Clin Biol Res; 1989 Oct 20; 303():69-74. PubMed ID: 2528742
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.